13046_2017_509_MOESM4_ESM.tif (60.79 kB)
Additional file 4: Figure S3. of Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
figure
posted on 2017-02-28, 05:00 authored by Yoshitaro Shindo, Shoichi Hazama, Nobuaki Suzuki, Haruo Iguchi, Kazuhiro Uesugi, Hiroaki Tanaka, Atsushi Aruga, Takashi Hatori, Hidenobu Ishizaki, Yuzo Umeda, Toshiyoshi Fujiwara, Tetsuya Ikemoto, Mitsuo Shimada, Kazuhiko Yoshimatsu, Hiroko Takenouchi, Hiroto Matsui, Shinsuke Kanekiyo, Michihisa Iida, Yasunobu Koki, Hideki Arima, Hiroyuki Furukawa, Tomio Ueno, Shigefumi Yoshino, Tomonobu Fujita, Yutaka Kawakami, Yusuke Nakamura, Masaaki Oka, Hiroaki NaganoFrequency of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells. (a), (c) There were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells in the 46 patients before and after treatment. (b), (e) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 19) in the HLA-A*2402-matched group. (c), (f) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 15) in the HLA-A*2402-unmatched group. (TIF 60 kb)
